PDL BioPharma (PDL BioPharma) Forward Dividend Yield % : 0.00% (As of May. 10, 2024)

View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Forward Dividend Yield %?

As of today (2024-05-10), the Forward Annual Dividend Yield of PDL BioPharma is 0.00%.

As of today (2024-05-10), the Trailing Annual Dividend Yield of PDL BioPharma is 0.00%.

PDLI's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.44
* Ranked among companies with meaningful Forward Dividend Yield % only.

PDL BioPharma's Dividends per Share for the three months ended in Jun. 2020 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of PDL BioPharma's Forward Dividend Yield %

For the Biotechnology subindustry, PDL BioPharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDL BioPharma's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's Forward Dividend Yield % falls into.

PDL BioPharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

PDL BioPharma (NAS:PDLI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

PDL BioPharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

PDL BioPharma (PDL BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

932 Southwood Boulevard, Incline Villiage, NV, USA, 89451

Website

http://www.pdl.com

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Executives

David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet	officer: President and CEO	C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone	officer: VP, Gen. Counsel & Secretary	932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar	director	9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday	director	932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno	officer: VP Finance, CAO and Acting CFO	932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene	officer: VP, Business Development	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick	director
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai	director	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia	officer: Vice President, CFO	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell	director	2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010